Go Pro
NASDAQ:CDXS

Codexis (CDXS) Stock Price, News & Analysis

Codexis logo
$1.56 -0.04 (-2.50%)
As of 08/14/2026 04:00 PM Eastern

About Codexis Stock (NASDAQ:CDXS)

Advanced

Key Stats

Today's Range
$1.51
$1.62
50-Day Range
$1.40
$2.66
52-Week Range
$0.96
$3.26
Volume
1.24 million shs
Average Volume
1.64 million shs
Market Capitalization
$170.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Hold

Company Overview

Codexis, Inc., headquartered in Redwood City, California, is a leading protein engineering company focused on the development of innovative enzyme solutions for pharmaceutical, food and beverage, and specialty chemical applications. The company’s proprietary directed evolution platform, CodeEvolver®, enables the rapid identification and optimization of enzymes with enhanced activity, selectivity and stability. By leveraging this technology, Codexis provides custom biocatalysts designed to improve manufacturing efficiency and reduce environmental impact.

Since its founding in 2002, Codexis has expanded its capabilities from early-stage research to commercial-scale production. The company operates advanced research and development laboratories alongside cGMP manufacturing facilities, allowing for seamless scale-up of enzyme processes. Its multidisciplinary team of molecular biologists, biochemists and process engineers collaborates closely with clients to integrate tailored enzyme solutions into existing production workflows.

Codexis’s biocatalysts have been applied to the synthesis of active pharmaceutical ingredients, delivering streamlined routes and cost reductions in drug manufacturing. Beyond pharmaceuticals, the company addresses challenges in the food and beverage sector—such as flavor enhancement and ingredient processing—and in the fine chemicals and agricultural markets. Codexis’s commitment to sustainable biocatalysis supports industry efforts toward greener chemistry and resource conservation.

Serving a global customer base, Codexis engages in partnerships and licensing arrangements with leading industrial and pharmaceutical organizations. Its commercial model typically combines research funding, milestone payments and royalty streams, positioning the company for diversified revenue growth across multiple projects. With an emphasis on innovation and environmental stewardship, Codexis continues to drive advancements in the burgeoning field of enzyme-based manufacturing.

AI Generated. May Contain Errors.

Codexis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
59th Percentile Overall Score

CDXS MarketRank™: 

Codexis scored higher than 59% of companies evaluated by MarketBeat, and ranked 377th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Codexis has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

  • Upside Potential

    Codexis has a consensus price target of $5.00, representing about 220.5% upside from its current price of $1.56.

  • Amount of Analyst Coverage

    Codexis has only been the subject of 2 research reports in the past 90 days.

  • Read more about Codexis' stock forecast and price target.
  • Earnings Growth

    Earnings for Codexis are expected to grow in the coming year, from ($0.37) to ($0.24) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Codexis is -4.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Codexis is -4.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Codexis has a P/B Ratio of 5.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Codexis' valuation and earnings.
  • Percentage of Shares Shorted

    4.48% of the float of Codexis has been sold short.
  • Short Interest Ratio / Days to Cover

    Codexis has a short interest ratio ("days to cover") of 2.06, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Codexis has recently increased by 4.72%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Codexis does not currently pay a dividend.

  • Dividend Growth

    Codexis does not have a long track record of dividend growth.

  • News Sentiment

    Codexis has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Codexis this week, compared to 2 articles on an average week.
  • Search Interest

    8 people have searched for CDXS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Codexis to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Codexis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,174.00 in company stock.

  • Percentage Held by Insiders

    3.50% of the stock of Codexis is held by insiders.

  • Percentage Held by Institutions

    78.54% of the stock of Codexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Codexis' insider trading history.
Receive CDXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CDXS Stock News Headlines

Codexis (NASDAQ:CDXS) Cut to Sell at Wall Street Zen
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
Codexis, Inc. (CDXS) Q2 2026 Earnings Call Transcript
Codexis Reports Second Quarter 2026 Financial Results
Codexis (CDXS) Expected to Release Quarterly Earnings on Tuesday
See More Headlines

CDXS Stock Analysis - Frequently Asked Questions

Codexis' stock was trading at $1.63 at the beginning of the year. Since then, CDXS shares have decreased by 4.3% and is now trading at $1.56.

Codexis, Inc. (NASDAQ:CDXS) issued its quarterly earnings results on Tuesday, August, 11th. The biotechnology company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.01. The biotechnology company earned $14.92 million during the quarter, compared to the consensus estimate of $13.82 million. Codexis had a negative net margin of 39.55% and a negative trailing twelve-month return on equity of 74.36%.
Read the conference call transcript
.

Codexis (CDXS) raised $0 in an initial public offering (IPO) on Thursday, April 22nd 2010. The company issued 0 shares at $0.00-$13.00 per share.

Codexis' top institutional investors include BlackRock Inc. (8.01%), Assenagon Asset Management S.A. (1.41%), Post Resch Tallon Group Inc. (0.62%) and Algert Global LLC (0.39%). Insiders that own company stock include Opaleye Management Inc, Alison Moore, Byron L Dorgan, Stefan Lutz, Kevin Norrett, Vre Raymond De, Margaret Nell Fitzgerald and Georgia Erbez.
View institutional ownership trends
.

Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Codexis investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Walt Disney (DIS) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
8/11/2026
Today
8/15/2026
Next Earnings (Estimated)
10/29/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Life Sciences Tools & Services
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:CDXS
CIK
1200375
Employees
250
Year Founded
2002

Price Target and Rating

High Price Target
$5.00
Low Price Target
$5.00
Potential Upside/Downside
+220.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.37)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$43.97 million
Net Margins
-39.55%
Pretax Margin
-39.46%
Return on Equity
-74.36%
Return on Assets
-23.58%

Debt

Debt-to-Equity Ratio
1.03
Current Ratio
3.06
Quick Ratio
5.23

Sales & Book Value

Annual Sales
$70.39 million
Price / Sales
2.43
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.30 per share
Price / Book
5.20

Miscellaneous

Outstanding Shares
109,510,000
Free Float
105,673,000
Market Cap
$170.84 million
Optionable
Optionable
Beta
2.54

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:CDXS) was last updated on 8/15/2026 by MarketBeat.com Staff.
From Our Partners